Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
Roche’s Phase III trial of fenebrutinib in RMS meets primary endpoint
Roche has reported that the pivotal Phase III FENhance 1 trial of its investigational Bruton’s tyrosine kinase (BTK) inhibitor, fenebrutinib, …
-
PHCbi unveils cell expansion system for research use
PHC Corporation’s Biomedical Division (PHCbi) has introduced the cell expansion system, LiCellGrow, designed for research purposes in Japan and certain …
-
Kairos Pharma signs deal for Celyn Therapeutics’ CL-273
Kairos Pharma has signed a binding agreement to acquire exclusive worldwide rights to CL-273 from Celyn Therapeutics, a company backed …
-
FDA grants PMA to Synergy’s cervical disc
Synergy Spine Solutions has received premarket approval (PMA) from the US Food and Drug Administration (FDA) for the Synergy Disc, …
-
Opus Genetics reports Phase I/II trial results of OPGx-BEST1 gene therapy
Opus Genetics has reported early findings from its ongoing Phase I/II clinical trial of the OPGx-BEST1 gene therapy for the …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
BioMarin receives FDA approval for Palynziq use in adolescents
BioMarin Pharmaceutical has received the US Food and Drug Administration (FDA) approval for its supplemental biologics licence application (sBLA) for …
-
Quotient and Ipsen extend partnership for ultra-rare disease therapy
Quotient Sciences has extended its commercial partnership with Ipsen, focusing on the production of Sohonos (Palovarotene) for fibrodysplasia ossificans progressiva …
-
ENDRA reports favourable data from Taeus Liver device study in MASLD
ENDRA Life Sciences has reported results from a clinical study showing the Taeus Liver device’s high measurement consistency in metabolic …
-
Lilly reports ACHIEVE-3 trial outcomes for type 2 diabetes
Eli Lilly and Company has reported detailed findings from the ACHIEVE-3 Phase III trial comparing the efficacy and safety of …
-
Quantum acquires NeuWave Medical to enhance tumour ablation treatments
Quantum Surgical has acquired NeuWave Medical, supporting its strategy to broaden access to robotic-assisted tumour ablation treatments for reducing cancer …
-
Mahzi doses first patient in MZ-1866 trial for Pitt Hopkins syndrome
Mahzi Therapeutics has dosed the first patient in its Phase I/II UNITE study assessing MZ-1866, an investigational gene therapy targeting …
-
Novo Nordisk and Vivtex collaborate for oral medicines development
Novo Nordisk and Vivtex have entered a partnership focused on developing next-generation oral biologic therapies to treat obesity, diabetes and …
-
Stryker unveils Synchfix EVT for flexible syndesmotic ankle fixation
US-based Stryker has launched Synchfix EVT, a flexible syndesmotic fixation device intended to simplify surgical procedures and support ankle stabilisation …
-
Vico Therapeutics initiates patient dosing for VO659 Phase I/IIa trial
Vico Therapeutics has started patient dosing in an expanded cohort under a twice-yearly regimen for its Phase I/IIa clinical trial …
-
NorthX Biologics and Demeetra collaborate on GMP manufacturing and CLD
NorthX Biologics and Demeetra have entered a strategic partnership focused on integrated cell line development (CLD) and good manufacturing practice …
